Ironwood guides FY2024 adj EBITDA >$150M, LINZESS low-single digit growth, pipeline catalysts

IRONWOOD PHARMACEUTICALS INC

Maintains FY2023 guidance: LINZESS net sales growth 6-8%, revenue $435-450M, adjusted EBITDA ~($900M) from VectivBio charge.
FY2024 guidance: LINZESS U.S. net sales low-single digit % growth, total revenue $435-455M, adjusted EBITDA >$150M.
Expects apraglutide STARS Phase 3 topline data in SBS-IF in March 2024; CNP-104 Phase 2 topline data in PBC in Q3 2024.
High-single digit LINZESS prescription demand growth in 2024 offset by mid-to-high single digit price erosion from Medicaid AMP cap removal.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRONWOOD PHARMACEUTICALS INC reported full year 2024 results: revenue $435 - $455 million. Guidance initiated.

Period: full year 2024
Revenue: $435 - $455 million
Guidance: initiated
Result: guidance update

Exact text from the filing

- 8% Low-single digits % High-single digit prescription demand growth offset by mid to high-single digit price erosion primarily due to Medicaid AMP cap removal Total revenue $435 - $450 million $435 - $455 million Adjusted EBITDA 1 ~($900) million Reflects ~$1.1 billion one-time charge from acquisition of VectivBio >$150 million Excludes potential

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-001989

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.